Advances in Targeted Therapy in Chronic Lymphocytic Leukemia (CLL): Venetoclax Clinical Update
This webinar was recorded on December 1, 2023
Sponsored by Abbvie
This webinar aims to understand the evolution of the treatment landscape, goals of treatment, and managed care considerations in Chronic Lymphocytic Leukemia (CLL) and to provide an update on the new clinical and health-economic data for Venclexta® (venetoclax) in the treatment of patients living with CLL. The target audience for this program includes medical directors, pharmacy directors, chief pharmacy officers, quality directors, case managers, and other stakeholders with healthcare access decision-making responsibilities.
At the conclusion of the webinar participants will be able to:
- Discuss the CLL disease state, evolving treatment goals, and remaining unmet needs
- Describe the efficacy and safety of Venclexta® (venetoclax) fixed treatment duration regimens in CLL
- Provide an overview of the patient and health-economic benefits of Venclexta® (venetoclax) regimens that allow time off therapy in CLL
- Outline patient, disease, clinical and health-economic considerations for managed care in the treatment of CLL
Dr. Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology) at Stanford Cancer Institute, Stanford HealthCare
Venclexta® (venetoclax) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
For Full Prescribing information, please see www.rxabbvie.com/pdf/venclexta.pdf
This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenter are those of the sponsor or presenter and not of AMCP.